Potential therapies for acute-on-chronic liver failure

Maura A. Morrison, Florent Artru, Francesca M. Trovato, Evangelos Triantafyllou, Mark J. McPhail*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

9 Citations (Scopus)


Acute-on-chronic liver failure (ACLF) is a syndrome that develops in approximately 30% of patients hospitalised with cirrhosis and is characterised by an acute decompensation of liver function associated with extra-hepatic organ failures and a high short-term mortality. At present, no specific therapies are available for ACLF, and current management is limited to treatment of the precipitating event and organ support. Given the high prevalence and high mortality of this severe liver disease, there is an urgent need for targeted treatments. There is increasing evidence of the important role played by systemic inflammation and immune dysfunction in the pathophysiology of ACLF and a better understanding of these immune processes is resulting in new therapeutic targets. The aim of this review is to present an overview of ongoing studies of potentially promising therapies and how they could be utilised in the management of ACLF.

Original languageEnglish
Publication statusAccepted/In press - 2023


Dive into the research topics of 'Potential therapies for acute-on-chronic liver failure'. Together they form a unique fingerprint.

Cite this